6.2 Neonatal Seizures & Intraventricular Hemorrhage (IVH)

6.2 Neonatal Seizures & Intraventricular Hemorrhage (IVH)

Neonatal seizures and intraventricular hemorrhage (IVH) represent two of the most critical neurological disorders encountered in the neonatal nursery. Seizures are rarely idiopathic in the newborn; they serve as a cardinal clinical sign of underlying central nervous system injury, metabolic decompensation, or systemic illness. Intraventricular hemorrhage, primarily affecting very low birth weight preterm infants, arises from the anatomical fragility of the developing cerebral microvasculature and requires meticulous neuroprotective nursing care.

---

1. Neurobiology & Pathophysiology of Neonatal Seizures

The neonatal brain is uniquely susceptible to epileptic activity due to developmental imbalances between neuronal excitation and inhibition. However, because cortical organization, axonal arborization, synaptic density, and myelination are incomplete, neonates rarely demonstrate generalized tonic-clonic seizures. Instead, neonatal seizures present as localized, migratory, or subtle behavioral and autonomic phenomena.

The Excitatory Paradox of GABA in the Immature Brain

In the mature adult brain, gamma-aminobutyric acid (GABA) is the primary inhibitory neurotransmitter. In the fetal and neonatal brain, however, GABA acts predominantly as an excitatory neurotransmitter:

• $NKCC1$ vs. $KCC2$ Expression: Immature neurons express high levels of the $NKCC1$ ($Na^+-K^+-2Cl^-$) co-transporter, which actively pumps chloride ions into the neuron, maintaining high intracellular chloride concentrations. The potassium-chloride co-transporter $KCC2$ (which expels chloride) is minimally expressed until later in neurodevelopment.
• Depolarization Upon GABA Activation: When GABA binds to $GABA_A$ receptors on neonatal neurons, ligand-gated channels open, allowing negatively charged chloride ions to flow out of the cell down their electrochemical gradient. This cellular loss of negative charge causes membrane depolarization (excitation) rather than hyperpolarization (inhibition), lowering the seizure threshold.
• Excess Glutamatergic Synapses: Concurrently, excitatory NMDA and AMPA glutamate receptors and receptor subunits are transiently overexpressed during early life to facilitate synaptic plasticity and brain growth, further tipping the balance toward neuronal hyperexcitability.

Metabolic Consequences of Prolonged Seizures

Seizure activity triggers a dramatic surge in cerebral metabolic rate for oxygen ($CMRO_2$) and glucose consumption. When cerebral substrate delivery fails to match hypermetabolic demand, intracellular ATP falls, lactic acid accumulates, cellular energy failure ensues, and excessive extracellular glutamate release causes excitotoxic neuronal injury.

---

2. Classification & Clinical Manifestations (Volpe Classification)

Joseph Volpe established the foundational clinical classification of neonatal seizures, dividing them into five major categories based on their semiology.

Volpe Neonatal Seizure Classification

---

3. Bedside Differentiation: Seizures vs. Benign Jitteriness

One of the most frequent clinical challenges in the neonatal nursery is distinguishing true epileptic seizures from benign neonatal jitteriness (tremors). Accurate differentiation prevents unnecessary anticonvulsant administration while ensuring rapid treatment of true status epilepticus.

Clinical Comparison: Jitteriness vs. True Seizures

4. Diagnostic Evaluation & Anticonvulsant Pharmacotherapy

When a neonatal seizure is recognized, clinical management proceeds simultaneously along two parallel tracks: emergency metabolic stabilization/diagnostic workup and pharmacological seizure cessation.

Acute Diagnostic Workup

1. Stat Bedside Blood Glucose: Immediate point-of-care capillary or arterial glucose. If blood glucose is < 45 mg/dL (2.5 mmol/L), immediately administer an IV bolus of $D_{10}W$ (10% Dextrose in Water) at 2 mL/kg (200 mg/kg) followed by a continuous glucose infusion rate (GIR) of 6 to 8 mg/kg/min.
2. Stat Serum Electrolytes: Total and ionized calcium (treat ionized $Ca^{2+} < 1.0\text{ mmol/L}$ with 10% Calcium Gluconate 100–200 mg/kg IV slowly), magnesium (treat $Mg^{2+} < 1.5\text{ mg/dL}$ with 50% Magnesium Sulfate 25–50 mg/kg IV/IM), sodium, and blood gas.
3. Infection Evaluation: Complete blood count, blood cultures, and lumbar puncture (LP) with CSF analysis (cell count, protein, glucose, Gram stain, viral PCR for Herpes Simplex Virus [HSV] and enteroviruses).
4. Neuroimaging & Electrophysiology: Continuous amplitude-integrated EEG (aEEG) or 24-channel conventional video-EEG (gold standard); bedside cranial ultrasound (for IVH and major structural lesions); brain MRI at 3 to 7 days of life.

Evidence-Based Anticonvulsant Medication Protocols

+------------------------------------------------------------------------------------------------------+
|                                 NEONATAL ANTICONVULSANT PATHWAY                                      |
|                                                                                                      |
|   [Step 1: First-Line]    -->   Phenobarbital: 20 mg/kg IV over 15–20 min                            |
|                                 * If seizures persist in 15m: repeat 5–10 mg/kg up to 40 mg/kg max   |
|   [Step 2: Second-Line]   -->   Levetiracetam (Keppra): 20–60 mg/kg IV over 15 min                   |
|                                 OR Fosphenytoin: 20 mg PE/kg IV (with cardiac monitoring)            |
|   [Step 3: Refractory]    -->   Midazolam Continuous Infusion: 0.1–0.4 mg/kg/hr                      |
|   [Step 4: Trial B6]      -->   Pyridoxine (Vitamin B6): 100 mg IV under continuous EEG              |
+------------------------------------------------------------------------------------------------------+

1. Phenobarbital (First-Line Gold Standard)

• Loading Dose: 20 mg/kg IV administered slowly over 15 to 20 minutes.
• Titration: If electrographic or clinical seizures persist after 15 to 20 minutes, administer additional increments of 5 to 10 mg/kg every 15–20 minutes up to a maximum cumulative loading dose of 40 mg/kg.
• Maintenance Dose: 3 to 5 mg/kg/day IV or PO divided every 12 hours, initiated 12 to 24 hours after the loading dose. Therapeutic serum level is 15 to 40 mcg/mL.
• Mechanism of Action: Allosterically binds $GABA_A$ receptors, prolonging the duration of chloride channel opening and enhancing inhibitory neurotransmission.
• Critical Nursing Alerts: High risk of acute respiratory depression (maintain emergency bag-mask ventilation, suction, and endotracheal equipment at bedside), systemic hypotension (monitor continuous blood pressure during infusion), and prolonged lethargy/hypotonia.

2. Levetiracetam (Keppra — Second-Line / Alternative First-Line)

• Loading Dose: 20 to 60 mg/kg IV infused over 15 minutes.
• Maintenance Dose: 20 to 40 mg/kg/day divided every 12 hours.
• Mechanism of Action: Binds selectively to synaptic vesicle protein SV2A, inhibiting presynaptic neurotransmitter exocytosis.
• Clinical Advantages: Minimal cardiorespiratory depression, no hepatic cytochrome P450 enzyme induction, and absence of neuroapoptotic properties in preclinical models.

3. Fosphenytoin (Second-Line Alternative)

• Loading Dose: 20 mg Phenytoin Equivalents (PE)/kg IV infused at a maximum rate of 1 to 2 mg PE/kg/min.
• Mechanism: Voltage-gated sodium channel blocker.
• Critical Nursing Alerts: Must maintain continuous electrocardiographic and blood pressure monitoring during infusion due to risks of cardiac arrhythmias, QTc interval prolongation, and hypotension.

4. Pyridoxine (Vitamin B6 Dependency Trial)

• Indicated for neonates with intractable, refractory seizures unresponsive to standard anticonvulsants.
• Protocol: Administer 100 mg IV Pyridoxine during continuous conventional EEG recording. A dramatic clinical and electrographic cessation of seizures within minutes confirms pyridoxine-dependent epilepsy (mutations in the ALDH7A1 gene encoding antiquitin).

---

5. Intraventricular Hemorrhage (IVH) & Post-Hemorrhagic Hydrocephalus

Intraventricular hemorrhage (IVH) is the most common intracranial hemorrhage in preterm infants, predominantly occurring in infants born at < 32 weeks gestation or with birth weight < 1,500 grams (highest incidence in extremely preterm infants < 28 weeks).

Anatomical Vulnerability: The Germinal Matrix

IVH originates within the subependymal germinal matrix, a transient, highly cellular, richly vascular embryonic structure located in the subependymal layer of the lateral ventricles (overlying the head of the caudate nucleus). The germinal matrix is the birthplace of neuronal and glial precursor cells during fetal development.

• Fragile Microvasculature: Germinal matrix capillary beds consist of large, irregular, thin-walled endothelial channels that lack muscular coats, internal elastic lamina, and structural collagen support.
• Pressure-Passive Cerebral Circulation: Preterm cerebral autoregulation is impaired. Any fluctuation in systemic blood pressure is directly transmitted to the fragile germinal matrix microvessels, leading to vessel rupture.
• Venous Stasis: The deep cerebral venous drainage (vein of Galen and internal cerebral veins) forms a sharp "U-turn" in blood flow at the level of the germinal matrix, predisposing to venous congestion, thrombosis, and rupture under conditions of increased intrathoracic or venous pressure.

Papile Grading of Intraventricular Hemorrhage

Clinical Presentation & Screening Ultrasound Schedule

• Timing of IVH: IVH is rarely present at birth. 50% occur on Day 1 of life, 75% by Day 2, and >90% by Day 3 (72 hours). Extension of hemorrhage can continue up to day 7.
• Clinical Presentation:
  • Catastrophic Deterioration: Sudden, rapid clinical collapse within minutes/hours characterized by acute pallor, hypotension, refractory bradycardia, severe apnea, flaccidity, bulging anterior fontanelle, fixed non-reactive pupils, sudden drop in hematocrit, metabolic acidosis, and intractable seizures.
  • Saltatory (Subtle / Stepwise) Presentation: Subtle, gradual deterioration over hours or days: intermittent hypotonia, fluctuating consciousness, increased ventilatory requirements, and minor hematocrit drops.
  • Clinically Silent (Asymptomatic): Over 50% of cases are completely asymptomatic and detected solely on routine screening ultrasound.
• AAP Screening Recommendations: Universal screening cranial ultrasound (CrUS) is recommended at 7 to 14 days of life for all infants born at < 32 weeks gestation, with a repeat scan performed at term-equivalent age (36 to 40 weeks postmenstrual age) to evaluate for post-hemorrhagic ventricular dilation and periventricular leukomalacia (PVL).

Evidence-Based Preterm Neuroprotective Care Bundle

+---------------------------------------------------------------------------------------------------+
|                                 PRETERM NEUROPROTECTIVE BUNDLE                                    |
|                                                                                                   |
|   1. Midline Head Positioning (0–30° elevation; avoid jugular venous compression)                 |
|   2. Avoid Rapid Fluid Boluses (administer crystalloids/blood slowly over 30–60 min)              |
|   3. Maintain Normocarbia (target PaCO2 45–55 mmHg; avoid hypocarbia and hypercarbia)            |
|   4. Gentle Endotracheal Suctioning (suction only when clinically indicated, not routine)         |
|   5. Minimal Handling & Clustered Care (protect circadian rhythm, reduce stress/pain)             |
|   6. Antenatal Optimization (maternal Betamethasone & Magnesium Sulfate prior to birth)           |
+---------------------------------------------------------------------------------------------------+

Post-Hemorrhagic Ventricular Dilation (PHVD) & Management

• Blood breakdown products and inflammatory cytokines cause subarachnoid and arachnoid villi fibrosis (obliterative arachnoiditis) and aqueductal obstruction, impairing cerebrospinal fluid (CSF) reabsorption.
• Nursing Surveillance: Measure and plot daily Occipitofrontal Head Circumference (OFC); evaluate fontanelle tension, splayed cranial sutures, setting-sun eye sign, and monitor weekly cranial ultrasounds measuring the ventricular index (Levene curve).
• Interventions: Serial therapeutic lumbar punctures; temporary subcutaneous ventricular reservoir (Ommaya or Rickham reservoir) or subgaleal shunt with serial transcutaneous CSF aspirations; definitive surgical placement of a ventriculoperitoneal (VP) shunt once the infant reaches adequate weight (>2,000g) and CSF protein clears.